Financial News

Financial Report: Emergent BioSolutions

Contract manufacturing revenues up 20% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent BioSolutions   3Q Revenues: $164.9 million (+20%) 3Q Earnings: $36.9 million (+69%) YTD Revenues: $354.7 million (+17%) YTD Earnings: $29.5 million (earnings were $6.6 million YTD14) Comments: Product sales were $124.0 million, up 47% in the quarter driven by BioThrax sales, up 66% to $109.8 million. Revenue from contract manufacturing operations was $11.3 million, up 20% primarily due to the timing of fill/finish services to third parties. Contracts, grants and collaborat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters